Molecular Partners AG
MP0533
acute myeloid leukemia
Date
TBD
Phase 1 readout · Date TBD estimated
What's at stake
Phase 1 trial results for MP0533 in acute myeloid leukemia are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 12h ago
“Data presented at the 67th American Society of Hematology (ASH) Annual Meeting in December 2025 showed that densified dosing appears tolerable, and leads to markedly improved serum exposure in cycle 1 and encouraging preliminary antitumor a”